Debate Continues on When Best to Use Mesothelioma Chemotherapy

This study is pretty reassuring that half the patients aren’t getting a more optimal or superior approach,” Simone said. “Both are good, accepted approaches. It’s more what the institution is comfortable with, and how the doctors are trained to do it.” European Trial May Be More Definitive The ongoing clinical trial is being done at centers in Belgium, France and the Netherlands. The European Organization for Research and Treatment of Cancer is sponsoring the study. The goal is 64 patients, half of whom will undergo pleurectomy and decortication surgery followed by three cycles of pemetrexed and cisplatin chemotherapy. A second group will receive the same chemotherapy combination before the P/D procedure. “The primary objective of the study is to investigate the feasibility of immediate P/D, followed by chemotherapy, or deferred P/D after chemotherapy in patients with early stage malignant pleural mesothelioma,” the clinical trial authors wrote. The trial started in 2016, hoping to determine if one method is better than the other. Researchers plan to use the more advantageous procedure in a comparative study with either the extrapleural pneumonectomy surgery or a no-surgery control arm. The post Debate Continues on When Best to Use Mesothelioma Chemotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients &Families.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
chel L O’Donnell Dysfunctional homologous recombination DNA repair (HRR), frequently due to BRCA mutations, is a determinant of sensitivity to platinum chemotherapy and poly(ADP-ribose) polymerase inhibitors (PARPi). In cultures of ovarian cancer cells, we have previously shown that HRR function, based upon RAD51 foci quantification, correlated with growth inhibition ex vivo induced by rucaparib (a PARPi) and 12-month survival following platinum chemotherapy. The aim of this study was to determine the feasibility of measuring HRR dysfunction (HRD) in other tumours, in order to estimate the frequency and hence wid...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A team of researchers at the Cancer and Vascular Biology Research Center in Haifa, Israel, and the Langone Medical Center in New York collaborated on research of a common blood-clotting pathway. Targeting this pathway may offer a unique avenue for improving existing mesothelioma treatments. Researchers said the standard first-line chemotherapy for malignant pleural mesothelioma — a combination of Alimta (pemetrexed) and cisplatin — offers little benefit to most mesothelioma patients. “This treatment regimen confers a median progression-free survival of 5.7 months,” according to the study published ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Using proper patient selection, doctors in Leuven, Belgium, are extending mesothelioma survival times significantly with the controversial extrapleural pneumonectomy surgery. Despite a growing reluctance to perform the surgery within the United States and throughout much of Europe, mesothelioma specialists at University Hospitals KU Leuven have continued performing it with great success. Their 2018 single-center study of the extrapleural pneumonectomy (EPP) for pleural mesothelioma produced a 33.2-month median survival and a 24.2 percent five-year survival. “With our dedicated team, a patient can do well with this su...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract BACKGROUND: Pleural mesothelioma is a rare but aggressive form of cancer. Local recurrence represents the majority of treatment failures and overall survival (OS) outcomes remain dismal. Adding locoregional treatment with radiotherapy after surgical resection has been considered but its role remains uncertain. OBJECTIVE: The purpose of this study was to evaluate the outcomes of adjuvant radiation therapy (RT) for patients with malignant pleural mesothelioma. METHODS: The National Cancer Data Base (NCDB) was queried (2004-2013) for patients with malignant mesothelioma. Patients were divided into ...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsOur findings revealBAP1 to be a potential, easily trackable prognostic and predictive biomarker for PeM immunotherapy that refines PeM disease classification.BAP1 stratification may improve drug response rates in ongoing phases I and II clinical trials exploring the use of immune checkpoint blockade therapies in PeM in whichBAP1 status is not considered. This integrated molecular characterization provides a comprehensive foundation for improved management of a subset of PeM patients.
Source: Genome Medicine - Category: Genetics & Stem Cells Source Type: research
ConclusionsAnalysis of these data suggests that minimally invasive approach for peritonectomy procedures and HIPEC is feasible, safe and should be considered as part of the armamentarium for highly selected patients with peritoneal surface malignancies with limited tumour burden, defined as PCI of 10 or less and borderline tumours as low-grade pseudomyxoma and benign multicystic mesothelioma.
Source: Surgical Endoscopy - Category: Surgery Source Type: research
Dr. Mags Portman, a British trailblazer in the fight to prevent and control HIV, died Wednesday after a two-year battle with mesothelioma. She was 44. Portman was lauded for triggering a significant reduction in HIV diagnoses throughout the United Kingdom by her work as a researcher, clinician and outspoken advocate. She earned international acclaim for her work as an HIV consultant at London’s Mortimer Market Centre, a progressive sexual health clinic that made pre-exposure prophylaxis (PrEP) a reality in the U.K. Portman played a key role in the 2014 study at The Royal London Hospital that proved the efficacy of t...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Alimta | Asbestosis | Belgium Health | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemotherapy | Clinical Trials | Databases & Libraries | Environmental Health | France Health | Heart | Men | Mesothelioma | Netherlands Health | Study | University of Maryland | USA Health